Alector IPO Banks $176M to Test Alzheimer’s Drugs in Clinical Trials

Alector IPO Banks $176M to Test Alzheimer’s Drugs in Clinical Trials

Source: 
Xconomy
snippet: 

Alector, a company taking an immunotherapy approach to Alzheimer’s disease and other brain disorders, has raised approximately $176 million in an initial public offering.